Hydroxycarbamide-Vista capsules 500 mg No. 100

Hydroxycarbamide-Vista is indicated for the treatment of chronic myeloid leukemia, melanoma, bronchial carcinoma. In combination with radiotherapy, the drug is recommended for the treatment of malignant squamous cell tumors of the head and neck, as well as for choriocarcinoma of the uterus.

Composition

Active ingredient: 1 capsule contains 500 mg of hydroxycarbamide (hydroxyurea);

Excipients: lactose monohydrate, calcium citrate; sodium; magnesium stearate;

Capsule shell: gelatin, titanium dioxide (E 171).

Contraindication

Hypersensitivity to the active substance or to any other component of the drug. If hypersensitivity is detected during treatment, the drug should be discontinued.

Depressed bone marrow function (leukocyte count less than 2.5 × 10 9/l, platelet count less than 100 × 10 9/l) or severe anemia.

Method of application

Capsules should be swallowed whole, without chewing.

Therapy should be administered by a physician experienced in oncology and hematology. All dosing regimens should be based on the patient's actual or ideal body weight (whichever is lower).

Application features

Pregnant women

Contraindicated.

Children

Contraindicated.

Drivers

The reaction rate may be impaired when using hydroxyurea. This should be taken into account when increased attention is required, for example when driving vehicles and operating machinery.

Overdose

Patients who received the drug in doses several times higher than the usual recommended doses experienced pain, purple erythema, swelling of the palms of the hands and soles of the feet with subsequent peeling of the skin of the hands and feet, intense generalized skin hyperpigmentation, and severe acute stomatitis. In these cases, the drug should be temporarily discontinued.

Side effects

From the side of the hematopoietic and lymphatic systems:

From the gastrointestinal tract:

From the genitals and mammary glands:

Interaction

In case of simultaneous use with other myelosuppressive drugs or radiation therapy, the degree of bone marrow suppression or the development of other side effects may increase.

Since there is a possibility that the use of the drug will lead to an increase in the content of uric acid in the blood, it may be necessary to adjust the dose of uricosuric drugs (drugs that increase the excretion of uric acid from the body).

Storage conditions

Store out of the reach of children, at a temperature not exceeding 25 °C, in a place protected from light.

Shelf life - 4 years.